FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC
FDA also approved the QIAGEN therascreen® KRAS RGQ PCR kit (tissue) and the Guardant360® CDx (plasma) as companion diagnostics
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma
FDA also approved FoundationOne® CDx for selection of patients with FGFR2 fusion or other rearrangement as a companion diagnostic device
Protective HPV Vaccine-Induced Antibody Titres Can Be Detected Up To 12 Years After Vaccination
Findings from a follow-up analysis of data from 2 to 12 years after vaccination
EMA Recommends Extension of Indications for Pembrolizumab
New indication concerns the first-line treatment of advanced oesophageal carcinoma or gastroesophageal junction adenocarcinoma
FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
FDA also approved the Guardant360® CDx as a companion diagnostic
EMA Recommends Extension of Indications for Cemiplimab
New indications concern the treatment of basal cell carcinoma and non-small cell lung cancer
EMA Recommends Extension of Indications for Nivolumab and Ipilimumab
New indication concerns a combination of two drugs for the treatment of dMMR or MSI-H metastatic colorectal cancer
FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer
Evidence for efficacy is based on the results from the CHECKMATE-577 study
An Oncology Hospital at Home Model of Acute Care Shows Promise
Innovative model of oncology care may reduce unplanned healthcare utilisation and costs in cancer care delivery
Immune Checkpoint Inhibitor Induced Thyroiditis Associated with a Large Reduction in Death
In a large analysis, the association between thyroiditis and overall survival varied by tumour type, but was strongest in patients with lung cancer
BRAF Inhibitor and Rituximab for the Management of Refractory or Relapsed HCL
A chemotherapy-free regimen of vemurafenib and rituximab induced a durable complete response in most patients with refractory or relapsed hairy-cell leukaemia
Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based COVID-19 Vaccine
No seroconversion found upon a single dose in elderly cancer patients and those treated with chemotherapy, a reason for not extending the period between the two injections